NYKODE-THERAPEUTICS
Nykode Therapeutics (formerly Vaccibody*) ) (Euronext Growth (Oslo): VACC), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases.
The agreement includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, all of which being eligible for milestone and royalty payments. The vaccines will combine Regeneron’s unique antigen selection expertise and innovative VelociSuite ® in vivo models with Nykode Therapeutics’ modular vaccine platform and expertise in vaccine design. Nykode Therapeutics will be responsible for vaccine generation and characterization, as well as product supply through the end of Phase 1 trials. Regeneron will be responsible for antigen identification, preclinical and clinical development, manufacturing (from the end of Phase 1 trials) and commercialization.
Under the terms of the agreement, Nykode Therapeutics will receive a USD 30 million upfront payment and a USD 20 million equity investment at a premium of 20% on a 30-day volume weighted average price of the Nykode Therapeutics share for the last 30 trading days before the effective date of the agreement. Additionally, Nykode Therapeutics will potentially be eligible to receive more than USD 875 million in milestone payments, plus high single-digit to low double-digit tiered royalties on sales of commercialized products arising from the collaboration, bringing the total potential value of the agreement to more than USD 925 million, plus royalties. Regeneron will cover costs for research, as well as potential clinical, regulatory, manufacturing and commercialization activities.
Michael Engsig, CEO of Nykode Therapeutics, said: “We are very pleased to have entered into this groundbreaking agreement with Regeneron that may accelerate the expansion of our pipeline and fully leverage our unique and modular vaccine technology platform within multiple, large and commercially significant disease areas, in line with our corporate strategy. The agreement further validates Nykode Therapeutics’ position as a leading next-generation immunotherapy platform company. We are thrilled about the choice of programs and their therapeutic potential within cancer, and prophylactic and therapeutic potential within infectious diseases.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued: “Regeneron has generated unique know how in selecting and validating immunogenic antigens from extensive analysis of patient material. These can now be incorporated into our vaccine platform to deliver the antigens directly to antigen presenting cells and optimize the likelihood of inducing strong and broad clinically relevant immune responses. Regeneron has also developed a unique suite of proprietary VelociSuite ® technologies and in vivo models that can accelerate and improve the traditional drug development process, and they will use their deep clinical expertise to guide development of these novel vaccines. Therefore, Regeneron will be a tremendous partner as we work to bring multiple additional vaccines based on our technology platform to patients in the fastest and broadest manner and complement the expansion and acceleration of internal programs.”
Mikkel W. Pedersen, Chief Scientific Officer of Nykode Therapeutics, added: “We are excited about the opportunity to work with the Regeneron team. The extensive disease biology expertise of Regeneron coupled with Nykode Therapeutics’ modular and targeted vaccine platform will enable us to design and potentially bring into the clinic new unique therapeutic vaccine concepts within both oncology and infectious diseases.”
Gavin Thurston, Ph.D., Senior Vice President, Oncology Research, at Regeneron said: “Collaborating with Nykode Therapeutics will bring another dimension to Regeneron’s already robust research and development programs for oncology and infectious disease and, in particular, provides new opportunities to help people with challenging tumor types or infectious diseases with high unmet need. Nykode Therapeutics’ platform efficiently delivers vaccine payloads to antigen presenting cells and allows for vaccine candidates that can be easily manufactured. It has already shown robust CD8+ antigen-specific T cell responses in animal models and in patients with cancer. Combining their platform with our industry-leading VelociSuite ® technologies and expertise may help to accelerate this emerging and promising therapeutic approach.”
Webcast
CEO Michael Engsig and other members of management will host a webcast on November 23, 2021 at 4 p.m. CET / 10 a.m. EST to present the license and collaboration agreement with Regeneron. The slides will be made available before the webcast. The webcast may be viewed here:
https://channel.royalcast.com/landingpage/hegnarmedia/20211118_4/
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration agreement with Regeneron within oncology and infectious diseases, and a collaboration with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006740/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Core42 “Maximus-384” Cluster Secures Top 20 Ranking on the Global TOP500 Supercomputers List18.11.2025 14:24:00 CET | Press release
Core42, A G42 Company, secures #20 position with its AMD Instinct MI300X GPU cluster in Buffalo, New York.Results announced ahead of Supercomputing 2025.Collaboration between Core42, Broadcom and Arista Networks delivers a top performing and reliable HPC network with fast data transfers and minimal latency. Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced that itsMaximus-384 supercomputer has been ranked No. 20 globally on the TOP500 List, the industry’s most recognized benchmark for publicly known supercomputing systems. The ranking highlights the performance of the AMD Instinct™ MI300X GPU-based “Maximus” cluster, operated at the company’s facility in Buffalo, New York and released ahead of Supercomputing 2025, the leading global conference for HPC. The TOP500 list tracks performance trends across the global supercomputing systems using the High Performance Linpack benchmark (HPL) benchmark. Securing a top-20 position reflects exceptional enginee
Armis Streamlines Network and Security Operations by Utilizing Keysight’s Application Fusion Platform18.11.2025 14:00:00 CET | Press release
Armis' technology can now run on the Keysight Vision E1S network packet brokers using the open interface known as Application Fusion, empowering security teams to enhance efficiency, reduce infrastructure costs and strengthen their security posture Armis, the cyber exposure management & security company, and Keysight Technologies, Inc. (NYSE: KEYS) today announced that Armis’ cyber exposure management technology will now run directly on the Keysight Vision E1S network packet brokers, with additional models expected to support Application Fusion in the future. Through the Application Fusion interface, Armis’ technology can now run directly on the Keysight network packet brokers, combining network visibility with continuous cyber exposure management and security capabilities. By providing immediate, actionable insights across the entire network, without the need for additional hardware, security teams can respond to threats faster, proactively reduce risk and increase operational efficie
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis18.11.2025 14:00:00 CET | Press release
New method enables single cell discovery from archived tissue samples, expanding access to translational and clinical research Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraffin-embedded (FFPE) samples. By enabling whole transcriptome capture from archived tissues at single cell resolution, this innovation opens new possibilities for discovery in oncology, translational research, and precision medicine. The use of FFPE samples for single cell RNA sequencing (scRNA-seq) has traditionally been limited to profiling a predefined list of genes due to RNA degradation and fragmentation, reducing transcriptome coverage and discovery potential. Parse’s breakthrough overcomes these challenges with a novel split-pool combinatorial barcoding method that enables true transcriptome-wide scRNA-seq of FFPE-preserved tissues through its unique RNA captu
KP Labs and Frontgrade Gaisler Join Forces to Advance Fault-Tolerant Computing for Next-Generation Space Missions18.11.2025 14:00:00 CET | Press release
KP Labs, a European Leader in delivering autonomous systems for space applications and Frontgrade™ Gaisler Technologies, a leading provider of high-reliability electronic solutions for space and national security missions have signed a Memorandum of Understanding during the Space Tech Expo Europe in Bremen, Germany. The agreement establishes a framework for collaboration in developing and validating advanced on-board computing architectures designed to increase the autonomy and resilience of future space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118359687/en/ As satellite operators and mission designers increasingly rely on on-board data processing and autonomy, maintaining fault tolerance and reliability has become a critical priority. To meet these demands, modern spacecraft integrates radiation-hardened components and advanced FDIR (Fault Detection, Isolation and Recovery) systems that ensure stable oper
ACE Fiber uses Adtran’s Mosaic One Clarity AI solution for proactive assurance, faster resolution and fewer truck rolls18.11.2025 14:00:00 CET | Press release
News summary: Mississippi provider’s fiber expansion increased operational complexity, driving the need for quicker troubleshooting and fewer site visits With Adtran’s Mosaic One Clarity, built on its REAL AI platform, ACE Fiber is transforming operations to prevent issues and reduce costs Early results show up to 75% fewer tickets in the first month, cutting service calls and improving customer experiences Adtran today announced that ACE Fiber, the broadband subsidiary of Mississippi’s ACE Power, is using its Mosaic One Clarity solution, built on the REAL AI platform, to move from reactive troubleshooting to proactive assurance across ACE Fiber’s expanding network. Mosaic One Clarity consolidates network and in-home data, identifies likely root causes and provides guided actions that help teams resolve issues faster and avoid unnecessary site visits. By detecting early signs of fiber performance issues and showing which subscribers are affected, Mosaic One Clarity enables more right-f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom